Cat. No.: DIA-0230286
Product Information | |
---|---|
CAS No. | 152121-30-7 |
Formula | C20H14FN3O |
Molecular Weight | 331.34 |
SMILES | OC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=NC=C3)C4=CC=C(F)C=C4 |
Product Description | SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. |
Format & Storage | |
---|---|
Purity | > 98% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.